QNCX, US22053A1079

Quince Therapeutics relaunched as IRulya: Raymond James targeted QNCX stock at USD 72

Published on 10/14/2026 at 02:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cash stood at USD 116 million on June 30, 2026. For QNCX stock, BOS data are expected in the first quarter of 2027.

Corporate reset and clinical dates

Raymond James initiated coverage on October 9, 2026, with a USD 72 price target.
Cash totaled USD 116 million on June 30, 2026, with funding expected through the end of 2028.
Trading under the IRLA ticker began on October 12, 2026, while further clinical milestones are scheduled for Q4 2026 and Q1 2027.

QNCX, US22053A1079, Illustration mit AI erstellt.

Quince Therapeutics (ISIN US22053A1079) relaunched as IRulya Therapeutics on October 9, 2026, while Raymond James initiated coverage with an Outperform rating and a USD 72 price target, as Markets Insider reported. The relaunch shifts the clinical-stage biotechnology company toward LAM-001, an inhaled rapamycin formulation for pulmonary diseases.

Three corporate milestones

On October 6, 2026, shareholders approved an issuance representing more than 20.00 percent of outstanding common shares, while the authorized share count rose from 250,000,000 to 275,000,000, according to StockTitan.

On October 9, 2026, the company name changed to IRulya Therapeutics and Series C preferred shares were scheduled for conversion, with approximately 10,841,470 common shares expected afterward, per Quince Therapeutics. On October 12, 2026, the shares began trading under the IRLA ticker on the Nasdaq Capital Market.

Clinical dates shape valuation

The company reported cash of USD 116 million as of June 30, 2026, and expects that balance to fund operations through the end of 2028, according to Quince Therapeutics. That runway gives the new strategy a measurable financial frame, but the investment case remains tied to clinical execution rather than commercial revenue.

What does the relaunch mean for the pipeline

IRulya plans to start a Phase 2 study of LAM-001 in sarcoidosis-associated pulmonary hypertension in the fourth quarter of 2026. Data from the ongoing bronchiolitis obliterans syndrome study are anticipated in the first quarter of 2027, while pulmonary hypertension associated with interstitial lung disease data are expected in the first quarter of 2028, according to Quince Therapeutics.

Nasdaq identity is changing

The last quoted Nasdaq price was USD 31.73 on October 9, 2026 at 4:00 p.m. ET. The USD 72 target from Raymond James therefore sits alongside a company undergoing a name, ticker, leadership and pipeline reset.

Market context: Market report S&P 500.